Table 3.
Genotype and allele frequencies of the IL-1β (+ 3954) polymorphism between women with and without endometriosis
| IL-1β | n | Genotype n (%) | Allele n (%) | ||||
|---|---|---|---|---|---|---|---|
| *1*1 | *1*2 | *2*2 | *1*2 + *2*2 | 1 | 2 | ||
| Women without endometriosis | 186 | 135 (72.6) | 46 (24.7) | 5 (2.7) | 51(27.4) | 316 (84.9) | 56 (15.1) |
| Women with endometriosis | 183 | 129 (70.5) | 47 (25.7) | 7 (3.8) | 54 (29.5) | 305 (83.3) | 61 (16.7) |
| Stage I | 63 | 51 (80.9) | 9 (14.3) | 3 (4.8) | 12 (19.0) | 111 (88.1) | 15 (11.9) |
| Stage II | 54 | 36 (66.7) | 16 (29.6) | 2 (3.7) | 18 (33.3) | 88 (81.5) | 20 (18.5) |
| Stage I/II | 117 | 87 (74.4) | 25 (21.4) | 5 (4.3) | 30 (25.6) | 199 (85.0) | 35 (15.0) |
| Stage III | 42 | 30 (71.4) | 11 (26.2) | 1 (2.4) | 12 (28.6) | 71 (84.5) | 13 (15.5) |
| Stage IV | 24 | 12 (50.0) | 11 (45.8)1 | 1 (4.2) | 12 (50.0)2 | 35 (72.9) | 13 (27.1) |
| Stage III/IV | 66 | 42 (63.6) | 22 (33.3) | 2 (3.0) | 24 (36.4) | 106 (80.3) | 26 (19.7) |
1x2 = 4.03, p = 0.044, OR = 2.69 (95% CI 1.11–6.51) versus women without endometriosis
2x2 = 4.14, p = 0.041, OR = 2.64 (95% CI 1.11–6.27) versus women without endometriosis